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Abstract:
This study is rooted in the research traditions of cultivation theory,
construct accessibility, and availability heuristic. Based on a survey with 221
subjects, this study finds that familiarity with direct-to-consumer (DTC) print
advertisements for antidepressant brands is associated with inflated
perceptions of the prevalence and lifetime risk of depression. The study
concludes that DTC advertising potentially has significant effects on
perceptions of depression prevalence and risk. Interpersonal experiences with
depression coupled with DTC advertising appear to significantly predict
individuals' perceived lifetime risk of depression. The study ultimately
demonstrates that DTC advertising may play a role in constructing social
reality of diseases and medicine. The findings strongly suggest that the social
cognitive effects of DTC advertising are far-reaching, impacting
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pharmaceutical marketing strategy as well as presenting issues regarding
public health and the business ethics of advertising drugs to consumers.

Introduction
Throughout the 1990s, direct-to-consumer (DTC) advertising
was one of the most rapidly growing categories of advertising (Davis,
2000). The U.S. expenditure on DTC advertising increased from $25
million in 1988 (Morgan and Levy, 1998), to $1.07 billion in 1996, and
to $2.7 billion in 2002 (U.S. General Accounting Office, 2003). By
2000, DTC advertising accounted for 15% of the total promotional
budget in the pharmaceutical industry (Brichacek and Sellers, 2001).
As a result, DTC advertising constituted 2.5% of the total advertising
expenditure in the U.S. market in 2000, (NIHCM, 2001) becoming the
fourth largest consumer-advertising category (Blankenhorn et al.,
2001).
Promoting prescription drugs directly to consumers has caused a
nation-wide controversy in the U.S. Opponents of DTC advertising
argue that it does not provide fair and balanced information about the
health benefits and risks of a drug (Bell et al., 2000; Coney, 2002).
They also point out DTC advertising may substantially increase health
care costs (Findlay, 2001), and adversely affects the doctor-patient
relationship, as doctors increasingly acquiesce to patients’ requests for
the drugs they see in DTC advertising (Bell et al., 1999; Mintzes et al.,
2002). In line with these critical viewpoints, in the race for 2004
Democratic presidential nomination, candidate Howard Dean called for
a ban on DTC advertising as an element of his 6-point plan to reduce
prescription drug costs. Two other candidates, Richard Gephardt and
John Edwards, expressed similar criticisms (Teinowitz, 2003).
In contrast, proponents argue the content of DTC advertising
has fair and balanced benefit and risk information and therefore can
educate consumers about diseases and treatments (Calfee, 2002).
They further argue DTC advertising can increase awareness of, and
encourage treatment of, stigmatized and under-diagnosed illnesses
such as hypercholesterolemia and clinical depression (Calfee, 2002;
Holmer, 2002). Proponents also points out that DTC advertising
encourages consumers to search for more information about health
conditions and treatments (Allison-Ottey et al., 2003; Perri and
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Dickson, 1988) as well as encourages compliance (Donohue et al.,
2004) and exerts positive influences on the doctor-patient interaction
(Holmer, 1999). In fact, when candidate Howard Dean's pledge to ban
DTC advertising received media coverage, Dan Jaffe, executive vice
president of the Association for National Advertisers, called the
candidate's plan “a prescription for disaster” and added, “[DTC]
advertising often provides consumers [with] extremely valuable
information that can save lives, often avoids serious health problems
and in so doing often lowers health costs” (Teinowitz, 2003, p. 1).
Since the “DTC explosion” in the 1990s, researchers have
explored how DTC advertising is associated with consumer attitudes,
intention and behavior. For example, Sumpradt et al. (2002) find
positive attitudes toward DTC advertising predicts willingness to
discuss advertised drugs with doctors. Beltramini (2006) further finds
consumers’ perceived believability and comprehension of information
in DTC advertising predict their plan to consult doctors about health
issues and request prescriptions for the specific drugs they saw in
advertising. When doctors refuse to prescribe the requested drugs,
many consumers are dissatisfied and insist on prescriptions for the
drugs (Bell et al., 1999; Mehta and Purvis, 2003). In fact, researchers
(Herzenstein et al., 2005; Kravitz et al., 2005) find consumers’
requests for drugs, based on exposure to DTC advertising, increase the
likelihood of doctors’ prescribing the drugs. At an industry level, Iizuka
and Jin (2005) find the pharmaceutical industry’s expenditures on DTC
advertising are associated with consumers’ increased visits to doctors’
offices. Zachry et al. (2002) further reveal the DTC expenditures for
antilipemics significantly predicts the number of diagnoses of
hyperlipidemia, prescriptions for antilipemics in general, and
prescriptions for Zocor. Overall, from a marketing perspective DTC
advertising appears to be successful.
Despite a large body of research, the current literature on the
effects of DTC advertising on consumers is limited for a number of
reasons. The literature is mostly centered around DTC advertising’s
impact on the way consumers seek health information and interact
with doctors to get specific drugs, focusing on variables such as
consumers’ awareness and attitudes regarding DTC advertising, visits
to doctors’ offices, requests for specific drugs, etc. These are
important variables and deserve attention. However, a body of
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literature from social cognition suggests DTC advertising can have
more far-reaching influences on the way consumers perceive the
“social reality” of diseases. Elliott (2003), a physician and professor of
bioethics, suggests as much. Using the case of Paxil, he argues that
“social reality” can be manipulated to the point where new disease
categories, such as “social anxiety disorder,” are largely constructed
by the pharmaceutical industry in an effort to expand drug therapy.
Elliott (2003) further argues that many drugs advertised to consumers
promote newly constructed diseases, and thus new disease categories
rather than promoting public heath.

Purpose of the study
Considering the minimal research available on the social
cognitive effects of DTC advertising, this study focuses on DTC
advertising’s potential influences on consumers’ perception of
diseases. Specifically, based on cultivation theory, construct
accessibility (Sherman and Corty, 1984) and availability heuristic
(Tversky and Kahneman, 1973), we will explore how consumers’
familiarity with DTC advertisements for one specific category of drugs,
antidepressants, is associated with their perceived social reality of
depression. We intend to achieve this purpose by testing how
consumers’ familiarity with DTC print advertisements for
antidepressants, namely Prozac (produced by Elli Lilly), Paxil CR
(GlaxoSmithKlein, GSK), Zoloft (Pﬁzer), Wellbutrin XL (GSK) and
Effexor XR (Wyeth), relates to their perceptions of the prevalence and
lifetime risk of clinical depression. In addition, we will also explore how
consumers’ interpersonal experiences with depression, namely
awareness of their personally meaningful others’ experiences with
depression, may be associated with their perceptions.
Of many categories of disease, this study focuses on depression
for a number of reasons. First, antidepressants, such as Paxil CR and
Zoloft, have been one of the most heavily advertised prescription drug
categories in the DTC market (Rosenthal et al., 2002). This may be
driven by the fact that depression is the most common form of severe
mood disorders (Altshuler et al., 1998; Weiss and Lonnquist, 1997).
Second, depression remains a largely under-diagnosed disease
category (Holmer, 2002). National Institute of Mental Health (NIMH,
2000) reports, “most people with a depressive illness do not seek
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treatment” (p. 1). In fact, it would be common for patients to
experience social stigma related to depression (Elliott, 2003; Holmer,
2002; Kravitz, 2000). Third, symptoms of depression, such as
loneliness, feeling of social isolation and worthlessness, and difficulty
with thinking (American Psychiatric Association, 1994), suggest DTC
antidepressants advertising is targeted toward a potentially vulnerable
group of consumers. Hollon (2004) points out special attention is
required regarding the effects of DTC advertising targeted toward
consumers suffering psychiatric and neurological illnesses, because
their decisional capacity may be impaired.
Last, Donohue and Berndt (2004) reveal pharmaceutical
companies’ expenditures on DTC antidepressant advertising are
associated with an overall increase in the number of prescriptions for
antidepressants. Apart from an increase in the requests for specific
drugs, they call this expansion of a drug category “a treatmentexpanding effect” (Donohue and Berndt, 2004, p. 124). Given that risk
perception generally increases intention to seek health information and
avoid risk behavior and prevent illnesses (Block and Keller, 1998;
Irwin et al., 1996; Raghubir and Menon, 1998; Siegel et al., 1998), we
believe that this study, addressing consumers’ prevalence and risk
perceptions of depression, will add valuable social cognitive insights to
the treatment-expanding power of DTC advertising; and thus
implications for public health and business ethics as well as marketing
strategy.

Theoretical background
Cultivation is a theory about the cumulative effects of television
consumption on viewer conceptions of social reality. Rooted in the
assumption that television dominates the “symbolic reality of modern
life”(Gerbner, et al., 1980, p. 5), cultivation theorists posit that the
amount of television watching is positively related to the degree to
which people’s beliefs about particular features of social reality mesh
with the way they are portrayed on television (Potter, 1993). This
occurs because viewers tend to integrate television information into
their conceptions of social reality (Potter, 1993).
Cultivation theorists have explored how television watching
predicts viewers’ perception of the prevalence of crimes and violence
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(Gerbner, et al., 1978, 1979, 1980; Hawkins and Pingree, 1980),
prostitution, alcoholism, and drug use (Shrum and O’Guinn, 1993), as
well as undesirable sexual behaviors such as teenage pregnancy and
marital infidelity (Woo and Dominick, 2003). Particularly relevant to
this study, a group of researchers have applied the theory to consumer
research. For example, O’Guinn and Shrum (1997) reported exposure
to soap operas is positively associated with consumers’ perceived
prevalence of the use of product categories symbolizing affluent
lifestyles. The association likely occurs because soap operas frequently
depict affluent lifestyles (O'Guinn and Shrum, 1997) and the television
world generally over-represents professionals and the upper middle
class, while under-representing the low class (Lichter et al., 1994).
The literature on social cognition indicates cultivation theory is
applicable for this study. Social cognition research has consistently
found people tend to use little information in making social estimates
(Taylor and Fiske, 1978; Wyer and Srull, 1989). Researchers (Higgins
et al., 1977; Roskos-Ewoldsen and Fazio, 1997; Taylor and Fiske,
1978) propose information, consisting of constructs, most accessible in
making social estimates tends to be used most frequently, a process
known as construct accessibility. In making social judgments, these
judgment-related accessible constructs come to mind as “exemplars”
of the judgment domain and influence overall social estimates (Shrum,
2003). Elliott (2003) contends pharmaceutical companies construct
depression as widespread and common through DTC advertising. We
propose such construction occurs as DTC advertising increasingly
disseminates exemplars with which consumers can make social
judgments. By means of activating a process of construct accessibility
(Sherman and Corty, 1984), DTC advertising may have a role in the
social construction of depression.
Further, more accessible information can also influence social
estimates through the principle of availability heuristic (Tversky and
Kahneman, 1973), which posits the more easily people can retrieve
information, such as relevant examples, from their memory regarding
a certain feature of social reality, the more prevalent or frequent they
perceive the phenomenon to be. The ease of retrieving relevant
information becomes a heuristic that tends to inflate individuals’
frequency and prevalence estimates of a phenomenon. We expect that
accumulated exposure to DTC advertisements for antidepressants will
Journal of Business Ethics, Vol. 79, No. 4 (2008): pg. 379-393. DOI. This article is © Springer and permission has been
granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article to be
further copied/distributed or hosted elsewhere without the express permission from Springer.

6

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

lead individuals to be more familiar with them, and familiarity will
make consumers’ memory regarding depression and antidepressants
more accessible.
A group of researchers (O'Guinn and Shrum, 1997; Shrum and
Bischak, 2001; Shrum and O'Guinn, 1993) propose the principles of
construct accessibility and availability heuristic account for the
psychological processes leading to cultivation effects. They suggest the
media frequently present relevant exemplars of a feature of social
reality, making these exemplars highly accessible. Consumers
comfortably make social estimates partly under the influence of these
exemplars, and the ease of retrieval of the exemplars tends to drive
up their social estimates (Shrum and O'Guinn, 1993). Similar to
television shows, advertising messages can function as a source of
information that can be stored in people’s memory and retrieved for
social judgments. For example, studies reveal consumers’ exposure to
advertising can increase the perceived ease of retrieving positive
attributes of a product (Menon and Raghubir, 2003) or their own
cognitive responses to an advertisement for it (Tybout et al., 2005),
influencing evaluations of the product.
This study is based on the assumption that DTC advertising for
antidepressant brands can be a source of accessible information that is
stored in consumers’ memory and influences their estimates of the
prevalence and lifetime risk of depression. An (2007) finds consumers’
unaided recall of print DTC antidepressant advertisements positively
predicts their perceived prevalence of depression. The study did not
control for interpersonal experiences with depression, while social
cognition researchers (Higgins and King, 1981; Shrum and Bischak,
2001; Wyer and Shrull, 1989) point out various modes of experiences
with a social phenomenon have influences on the perceived social
reality of the phenomenon. An (2007) also did not test the relationship
between recall and consumers’ own perceived lifetime risk of
depression.
Building on An (2007) and the studies in the past that exhibit a
relationship between media exposure and higher prevalence and risk
perceptions, we hypothesize that, after controlling for interpersonal
experiences with depression, the more familiar consumers are with
DTC advertisements for antidepressants, the more prevalent they will
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perceive clinical depression to be in the U.S. (H1), and the higher they
will perceive their own lifetime risk of depression to be (H2). We assert
familiarity is a more appropriate independent variable than recall to
predict social cognition, because recall requires active and intensive
information processing, while social judgments driven by availability
heuristic can be formed and retrieved through semi-conscious,
automatic information processing (Menon and Raghubir, 2003). In
fact, in An's (2007) study, 65% of survey respondents did not recall
any advertised antidepressant brand, and 25% recalled just one of the
five advertised brands. Familiarity can be retrieved and influence
judgments in a low-involvement, semiconscious manner (Hawkins and
Hoch, 1992).
Mass media are not the only information source to influence
consumers’ perceived social reality of depression. Individuals are
embedded in different life patterns and socio-cultural contexts, which
present alternative sources of retrievable information and therefore
can influence their perceptions of the prevalence and risk of
depression independent of the influences from mass media. Such
alternative information sources include memory of personal
experiences and interpersonal experiences, such as word-of-mouth
(Shrum and Bischak, 2001, p. 187). Higgins and King (1981) and
Wyer and Srull (1989) suggest information attained through personal
experiences is highly accessible when people think about a real-world
prevalence of a phenomenon related to such experiences.
We expect interpersonal experiences with depression,
conceptualized as knowing personally meaningful others (e.g. family
members, relatives and close friends) who suffer from clinical
depression and seek professional help, will also present a source of
accessible information when individuals report their perceptions of
depression, especially for those who have not experienced clinical
depression. Therefore, it is hypothesized that the more interpersonal
experiences individuals have with depression, the more prevalent they
will perceive clinical depression to be (H3) and the higher they will
perceive their own lifetime risk of depression to be (H4). This study
does not incorporate the role played by direct, personal experiences
with depression, because the overwhelming majority of study subjects
have not experienced clinical depression. Subjects who reported
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personal experiences with clinical depression were deleted from data
analysis.

Method
Subjects and procedure
A survey was conducted with a convenience sample of 221
undergraduates enrolled in introductory advertising courses at a large
state university in the U.S. Of the subjects, 68.2% were females.
Subjects ranged in age from 17 to 27 (M = 20.01, SD = 1.29). The
majority were whites (71.9%), followed by Hispanics (17.6%),
African–Americans (4.1%), and Asian–Americans (3.6%). Subjects
were largely from middle (29.9%) or upper middle class (54.8%)
families. Only 2.7% reported they were from working class families.
Subjects received extra credit for participation. The class
curriculum did not include topics that could have sensitized subjects to
the purpose of this study. Survey instruments were distributed in
class, but subjects completed them in private at home. Though less
preferable than a random sample from the general population,
undergraduates form a solid sample for this study, because consumer
socialization and expressions of social reality begin at early life stages
(John, 1999; Singh et al., 2003), and depression is increasingly
prevalent among young adults (Kessler et al., 2001). However,
homogeneity of the sample might yield results different from those
found in the general population. Therefore, one should take caution
when interpreting ﬁndings of this study.

The instrument
To help subjects differentiate clinical depression, which is the
focus of this study, from short periods of sadness, the cover sheet
explicitly stated, “depression is defined in this project as a form of
medical illness, or a state of sadness that has reached the point of
persistently disrupting a person’s social functioning and daily
activities.” In addition, for comparability of subjects’ responses with
nation-wide epidemiological data for depression, (Kessler et al., 1994;
National Comorbidity Survey, 2003; Regier et al., 1993), the cover
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sheet further emphasized that we defined “adults” as “American men
and women of 18 and over.”
Besides the dependent and independent variables, the
instrument measured a few control variables, such as socio-economic
status (SES), gender and interest in DTC advertising, which likely have
external influences on the relationships we hypothesized. For example,
SES is reported to be associated with media use patterns (Condry,
1989) and an increased risk of depression (Gilman et al., 2003). SES
may also influence consumers’ perceptions of social reality (Hawkins
and Pingree, 1980; Stroman and Seltzer, 1985). Women’s lifetime risk
of depression is twice as high as that of men (Kornstein and Wojcik,
2002), which may influence their perceived social reality of depression.
At the same time, women’s media use patterns differ from men’s in a
way that can influence their perception of depression. For example,
Reader’s Digest is a popular vehicle for DTC advertising with its
subscription rate being the second highest in the U.S., and its
readership is skewed towards women (MediaMark, 2002).
In addition, the assumed causal interpretation for the
relationships between familiarity with DTC advertisements and
consumers’ social reality perceptions is that DTC advertising influences
perceptions, rather than the other way around. A viable alternative
interpretation will be that those who have inflated perception of
depression may be interested in DTC advertising, and then become
more familiar with DTC antidepressant advertisements. The design of
this study significantly reduces this possibility by controlling the
interest for DTC advertising.
However a survey design cannot control all sources of external
influences. Therefore, one should be cautious in making causal
interpretations for the findings generated by this design.

Measures
Interest in DTC advertising
Subjects reported their interest in DTC advertising on a sevenpoint scale (1 = not at all interested, 7 = extremely interested). On
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the average, responses were below the mid-point (M = 2.61, SD =
1.40).

Interpersonal experiences
Subjects checked “yes,” “no,” or “don't know” for each of the
three items asking if they know of someone among their significant
others, namely family members, relatives and friends, who have
suffered from depression, sought professional help to deal with it or
taken an antidepressant. A total of 132 subjects reported that they
knew of their significant others who suffered from depression, followed
by 128 subjects reporting they knew of someone who took
antidepressants. A total of 99 reported they knew of someone who
sought professional help to deal with depression. As the items were
internally consistent (α = .82), they were averaged to create a single
index score.

Familiarity with DTC advertisements for
antidepressants
The survey included six print advertisements for five brands of
antidepressants, including Prozac, Zoloft, Paxil CR, Wellbutrin XL, and
Effxor XR. The advertisements were all retrieved from 1997 to 2005
issues of Reader’s Digest. Except for Paxil CR, which was represented
by two advertisements, each brand was represented by one
advertisement. Two ads were used for Paxil CR because
advertisements for the brand exhibited considerable variations in
terms of overall themes and execution styles, compared to other
brands containing only minor variations. Subjects reported how
familiar they were with each of the six print advertisements on a
seven-point scale (1 = not at all familiar, 7 = extremely familiar). The
items exhibited sufficient internal consistency (α = .76), with a mean
of 2.46 (SD = 1.09). To minimize the risk of test effects, we measured
familiarity after prevalence and risk perceptions were measured.

Perceived lifetime risk of depression
Subjects reported in percentage the chances that they will suffer
from depression at some point during their lifetime. Female subjects
on the average perceived their lifetime risk to be 29.09% (SD =
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27.62), while males perceived the risk to be 31.33% (SD = 33.25). It
was notable that the two groups did not significantly differ in their
perception, considering that epidemiological studies indicate the risk is
20–25% for women and approximately 13% for men (Kessler, 1993,
1994; NCS, 2003). Therefore, male subjects had more inflated
perceptions of their lifetime risk of depression compared to women.

Perceived prevalence of depression
A composite measure of perceived prevalence of depression was
constructed by selecting and modifying six social reality measurement
items from the cultivation theory literature (O'Guinn and Shrum, 1997;
Shapiro, 1991; Shrum, 1996). Subjects reported in percentage their
“gut-level” estimates of the probability of the following particular
situations occurring in the U.S.
(Q1) In a typical year, what percentage of American adults will
suffer from depression?
(Q2) In a typical year, what percentage of American households
will have one or two members who suffer from
depression?
(Q3) In a typical year, what percentage of people with mental
illnesses will be categorized as depressive patients?
(Q4) In a typical year, what percentage of male adults will
suffer from depression in the US?
(Q5) In a typical year, what percentage of female adults will
suffer from depression in the US?
(Q6) In a typical year, what percentage of Americans will have
one or two family members, relatives or close friends who
suffer from depression?
The six items exhibited high internal consistency (α = .86), and
were averaged to create a single index score. Subjects’ overall
estimate ranged from 7.17 to 77.50 out of 100 in total (M = 38.01, SD
= 15.68). On the whole, subjects had inflated perceptions about the
prevalence of depression. For example, male subjects reported on the
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average that in a typical year, 28.09% (SD = 17.31) of male adults
and 35.56% (SD = 18.69) of female adults would experience clinical
depression in the U.S. Female subjects replied that 26.50% (SD =
14.04) of male adults and 35.52% (SD = 18.17) of female adults
would undergo depression in a typical year. It was notable that male
and female subjects equally overestimated the prevalence of
depression among male and female adults, because epidemiological
data indicate that about 9.5% of adults, 12% of female adults and 7%
of male adults in the U.S. suffer from clinical depression in any given
year (Regier et. al., 1993). A more recent study reveals 6.5% of
adults, 8.5% of female adults, and 4.7% of male adults reported that
they had experienced depression within the last 12–month period
before the survey was conducted (NCS, 2003).

Results
Zero-order correlations
As a preliminary analysis, zero-order correlations among all the
variables were run. Missing data were accounted for by list-wise
deletions. Table I shows that significant correlations were found among
some of the variables. Especially, a control variable, interest in DTC
advertising, was significantly associated with interpersonal experiences
with depression (r = .17, p < .05), familiarity with DTC advertisements
for antidepressants (r = .29, p < .001) and perceived lifetime risk of
depression (r = .16, p < .05), suggesting the variable could have had
external influences had it been not controlled for. There were no
moderate to strong associations among control and independent
variables, suggesting the models does not have a multicollinearity
problem.

Testing the hypotheses
Hypotheses 1 & 3
A hierarchical multiple regression model was built to test H1 &
H3, with list-wise deletions accounting for missing data. Gender, age,
ethnicity and SES were entered as the first step. Because ethnicity was
a nominal variable with five response categories, it was recoded into
four dummy variables, each representing one ethnic category. Interest
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in DTC advertising was entered as the second step, followed by
interpersonal experiences as the third step and familiarity with DTC
antidepressant advertisements as the fourth step. The dependent
variable was perceived prevalence of depression in the U.S.
H1 predicted that college students’ familiarity with DTC
advertisements for antidepressant brands would be positively
associated with perceived prevalence of depression in the U.S. The
results supported this prediction in the complete model (β = .18, p <
.02) (see Table II). H3 predicted that college students’ interpersonal
experiences with depression would be positively associated with
perceived prevalence. H3 was not supported. The coefficient for
interpersonal experiences was positive but did not reach statistical
significance (β = .11, p > .13) (see Table II). Familiarity with
advertisements explained 2.60% of the variances in perceived
prevalence of depression [F(1, 195) = 5.49, p < .02].

Hypotheses 2 & 4
A hierarchical multiple regression model was built to test H2 and
H4. The model was the same as the one used to test H1 and H3,
except that the dependent variable was perceived lifetime risk of
depression.
H2 predicted that familiarity with DTC advertisements for
antidepressants would be positively associated with perceived lifetime
risk of depression. This hypothesis was supported in the complete
model (β = .20, p < .01) (see Table III). H4 predicted that college
students’ interpersonal experiences with depression would be
positively associated with perceived lifetime depression risk. The
results also supported this prediction (β = .19, p < .01) (see Table
III), although the relationship became weaker than the zero-order
correlation (r = .23, p < .01) it had with perceived depression risk
(see Table I). Together, the two independent variables explained
7.30% of the variances in perceived lifetime depression risk [F(2, 194)
= 7.95, p < .001].
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Discussion
Based on the research traditions of cultivation theory, construct
accessibility and availability heuristic, this study finds that familiarity
with DTC print advertisements for antidepressant brands are positively
associated with perceptions of the prevalence and lifetime risk of
depression. Interpersonal experiences with depression, defined as the
awareness that their meaningful others have suffered from depression,
sought professional help, or taken antidepressant medication,
significantly predict perceived lifetime risk, but not perceived
prevalence of depression.
These findings suggest significant implications in terms of
marketing strategy, public health and the business ethics of
pharmaceutical advertising. We begin with the strategic marketing
implications. Putsis and Dhar (2001) suggest brand promotions
produce expansion of a new product category, in addition to brand
switching. This suggests promotions are not necessarily a zero-sum
game (Putsis and Dhar, 2001). Donohue and Berndt (2004) find DTC
advertising for antidepressants increases the number of prescriptions
for antidepressants, implying DTC advertising has potentiality to
expand the market of antidepressants. The findings of the current
study imply DTC advertising’s category expanding effect may occur
because consumers become familiar with DTC advertisements for
antidepressants, and the subjective judgment of familiarity potentially
leads them to perceive depression as more prevalent in the US and
estimate their own lifetime depression risk to be higher. Research on
health behavior shows consumers’ risk assessment of a health problem
may produce attitudinal and behavioral changes, such as engaging in
preventive and remedial behaviors (Block and Keller, 1998; Irwin et
al., 1996; Raghubir and Menon 1998; Siegel et al., 1998), including
consultation with doctors. Therefore, changes in risk perception
triggered by DTC advertising may drive consumers to visit doctors’
offices to discuss depression and/or request antidepressant treatment.
Considering that limited market size is one of the major reasons
that the introduction of a new product fails, when launching a new
drug category, the findings of this study imply pharmaceutical
companies may consider using marketing tools to make consumers
more aware of the prevalence and risk of the relevant disease
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category in addition to showing the drug’s competitive advantages. As
consumers become gradually more familiar with the disease category,
more emphasis may be placed on product differentiation, or points of
difference between brands in a drug category. This cycle appears to
characterize DTC advertising campaigns for antidepressants, as
campaigns for early market leaders, such as Prozac and Zoloft,
conveyed the message that clinical depression is common, while
campaigns for brands launched at a later stage emphasized points of
difference. For example, Paxil CR was positioned as a social anxiety
disorder treatment, while Wellbutrin XL was positioned as the first
antidepressant without sexual side effects. Unlike Prozac and Zoloft, all
DTC advertisements for Effexor XR and Wellbutrin XL feature female
models, implying the two brands are targeted at women.
The findings also have implications for public health. If DTC
advertising potentially influences consumers’ perceptions of the social
reality of depression, as the findings suggest, what impact will the
phenomenon have on consumer health? To that end, we suggest the
following three hypothetical situations to further conceptualize how
cultivation effects may have occurred in this study.
Situation 1: Consumers may largely have underrated
perceptions about the social reality of depression, and cultivation
effects lead them to have more realistic prevalence and risk
perceptions.
Situation 2: Consumers may largely have overrated perceptions
about the social reality of depression, and cultivation effects lead them
to have further inflated prevalence and risk perceptions.
Situation 3: Consumers may have perceptions more or less
evenly split around the figures presented by the epidemiological data,
and cultivation effects may only occur in a group with underrated or
overrated perceptions.
Cultivation effects are a positive social phenomenon in the first
situation, whereas the second situation indicates a negative
phenomenon. The third presents a more complex picture.
Regarding subjects’ perceptions of the prevalence of depression,
data for this study generally support the second scenario, because on
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the average subjects reported about 38% (SD = 18.01) of adults
experience clinical depression each year, whereas epidemiological
studies indicate that about 10% experience it (Regier et al., 1993). On
the other hand, regarding the perceived lifetime risk of depression,
male subjects reported that their risk would be 32% (SD = 33.29),
whereas females perceived it to be 29% (SD = 28.05). Epidemiological
studies suggest that the lifetime risk of depression is approximately
13% for men and 20–25% for women (Kessler, 1993, 1994; NCS,
2003).
Interestingly, females had fairly realistic risk perceptions while
males were largely unrealistic. When multiple regressions were
conducted separately for men (n = 70) and women (n = 151), the
coefficient for familiarity with antidepressant advertisements was .34
(r < .013) for men and .18 (r < .049) for women. This shows
cultivation effects regarding lifetime risk perception occurs more
strongly among men, who already have inflated perceptions, than
among women. Given that depression has been a largely underdiagnosed and stigmatized disease, leading consumers to have further
inflated risk perceptions may have positive behavioral consequences,
such as encouraging depressed people to visit a doctor’s office and
leading consumers to comply better with antidepressant medication
(Donohue et al., 2004). However, it may also have negative behavioral
influences, such as leading consumers to make unnecessary visits to
the doctor’s office and therefore driving up health costs (Findlay,
2001). Research may be conducted to further explore the behavioral
consequences of the cultivation effects observed in the current study.
The findings of this study also have implications for the business
ethics of pharmaceutical advertising. Public criticism is mounting
against DTC advertising, as opponents contend that consumers are
misled by DTC advertising. At FDA hearings they suggested the
possibility of placing a ban or moratorium on DTC advertising. To
defend DTC advertising, GSK sent 8,000 sales representatives out to
manage the public policy issue in its favor (Thomaselli, 2006). The
pharmaceutical industry’s professional association, the Pharmaceutical
Research Manufacturers of America (PhRMA), has been strong
proponents of DTC advertising. To that end, in August 2005, PhRMA
introduced codes of conduct aimed at providing advertisers with
guideline for DTC advertising (PhRMA, 2005, see Appendix A).
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What are the potential implications of PhRMA's principles for the
ethics of pharmaceutical advertising, especially regarding the research
findings of this study? The preamble to the principles states that a
“strong empirical record demonstrates that DTC communications about
prescription medicines serve the public health” by increasing
awareness of diseases (PhRMA, 2005). Therefore, PhRMA encourages
drug companies to promote disease awareness through DTC
advertising (see Principle 9 in Appendix A). However, none of the
principles refers to the possibility that becoming familiar with DTC
advertising for a disease category may result in leading consumes to
have overrated perceptions of the risk of the disease. This deletion
may be a potential threat to public health, especially when one
considers the research finding that the association between familiarity
with DTC antidepressant advertising and perceived risk of depression
was stronger among those, mostly consisting of male subjects, who
already have unrealistically high risk perceptions of depression.
PhRMA (2005) also emphasizes DTC advertising should be
designed to “responsibly educate the consumer about that medicine,
and, where appropriate, the condition for which it may be prescribed.”
Given risk perception’s potentiality to produce behavioral
consequences (Block and Keller, 1998; Irwin et al., 1996; Raghubir
and Menon, 1998; Siegel et al., 1998), PhRMA may consider
encouraging drug companies to include in DTC advertising information
on the prevalence and risk of developing the relevant disease. Such an
initiative will increase the educational value of DTC advertising, with
higher potentiality to “responsibly” increase consumers’ awareness
about diseases and medicine and discourage them from having
unrealistic perceptions about their vulnerability to the diseases. We
argue the PhRMA guideline will help solidify the business ethics of DTC
advertising and gain the public’s confidence in the value of the new
business practice only if it presents such specific and concrete
principles to pharmaceutical companies.

Limitations and further suggestions
The current study has a number of conceptual and
methodological limitations. First, although we alluded to causal
interpretations of data driven by the perspectives of cultivation theory
and availability heuristic, correlational data cannot establish causality.
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Therefore, the findings and their implications for pharmaceutical
marketing strategy, consumer health and business ethics should be
interpreted with caution. A further study with an experimental design
will generate data that allow solid causal interpretations. Equally
important, findings of this study relate specifically to DTC print
advertising for antidepressants. Future studies may augment the
external validity by incorporating both print and broadcast media,
because DTC advertising is frequently conducted through broadcast
media (Rosenthal et al., 2002) and consumers’ processing of
information in electronic media may be different from that in print
media. In addition, although this study is framed around an early age
group at which individuals form perceptions about diseases, it will be
interesting to explore how the theoretical perspectives apply to the
general population. It should also be noted that this study is based on
a convenience sample. Therefore the data do not provide conclusive
evidence for the research findings. Insightful as they are, we suggest
researchers replicate the research findings with a nationally
representative sample. Last, although cultivation theory does not
suggest a causal link between prevalence and risk perceptions,
Kalichman and Cain (2005) reveal that prevalence perceptions may
increase perceptions of risk. Therefore, one may organize a study to
construct and test a model of simultaneous interrelationships among
the key concepts discussed in the current project.
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Appendix
Table I Zero-order correlations
*p < .05 (2-tailed), **p < .01 (2-tailed).

Table II Summary of hierarchical regression
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Table III Summary of hierarchical regression

Appendix A
PhRMA's guiding principles for direct-to-consumer advertising
To express the commitment of PhRMA members to deliver DTC
communications that serve as valuable contributors to public health, PhRMA
has established the following voluntary guiding principles.

Principle 1.
These Principles are premised on the recognition that DTC advertising
of prescription medicines can benefit the public health by increasing
awareness about diseases, educating patients about treatment options,
motivating patients to contact their physicians and engage in a dialogue about
health concerns, increasing the likelihood that patients will receive
appropriate care for conditions that are frequently under-diagnosed and
under-treated, and encouraging compliance with prescription drug treatment
regimens.

Principle 2.
In accordance with FDA regulations, all DTC information should be
accurate and not misleading, should make claims only when supported by
substantial evidence, should reflect balance between risks and benefits, and
should be consistent with FDA approved labeling.
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Principle 3.
DTC television and print advertising which is designed to market a
prescription drug should also be designed to responsibly educate the
consumer about that medicine and, where appropriate, the condition for
which it may be prescribed.

Principle 4.
DTC television and print advertising of prescription drugs should
clearly indicate that the medicine is a prescription drug to distinguish such
advertising from other advertising for nonprescription products.

Principle 5.
DTC television and print advertising should foster responsible
communications between patients and health care professionals to help
patients achieve better health and a more complete appreciation of both the
health benefits and the known risks associated with the medicine being
advertised.

Principle 6.
In order to foster responsible communication between patients and
health care professionals, companies should spend an appropriate amount of
time to educate health professionals about a new medicine or a new
therapeutic indication before commencing the first DTC advertising campaign.
In determining what constitutes an appropriate time, companies should take
into account the relative importance of informing patients of the availability of
a new medicine, the complexity of the risk-benefit profile of that new
medicine and health care professionals’ knowledge of the condition being
treated. Companies should continue to educate health care professionals as
additional valid information about a new medicine is obtained from all reliable
sources.

Principle 7.
Working with the FDA, companies should continue to responsibly alter
or discontinue a DTC advertising campaign should new and reliable
information indicate a serious previously unknown safety risk.

Principle 8.
Companies should submit all new DTC television advertisements to the
FDA before releasing these advertisements for broadcast.
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Principle 9.
DTC television and print advertising should include information about
the availability of other options such as diet and lifestyle changes where
appropriate for the advertised condition.

Principle 10.
DTC television advertising that identifies a product by name should
clearly state the health conditions for which the medicine is approved and the
major risks associated with the medicine being advertised.

Principle 11.
DTC television and print advertising should be designed to achieve a
balanced presentation of both the benefits and the risks associated with the
advertised prescription medicine. Specifically, risks and safety information in
DTC television advertising should be presented in clear, understandable
language, without distraction from the content, and in a manner that supports
the responsible dialogue between patients and health care professionals.

Principle 12.
All DTC advertising should respect the seriousness of the health
conditions and the medicine being advertised.

Principle 13.
In terms of content and placement, DTC television and print
advertisements should be targeted to avoid audiences that are not age
appropriate for the messages involved.

Principle 14.
Companies are encouraged to promote health and disease awareness
as part of their DTC advertising.

Principle 15.
Companies are encouraged to include information in all DTC
advertising, where feasible, about help for the uninsured and underinsured.
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